Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LRAT | O95237 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22562799 | 0.85 | CA1 (0.39) | LMNAMAPK1KDM4EALOX15MEN1 | |
| SCHEMBL25312309 | 0.85 | LMNA (0.45) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL12917667 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL14748251 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL26878917 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL24980481 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL13217015 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL12589717 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL12019429 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT | |
| SCHEMBL26878966 | 0.81 | LGALS8 (0.41) | LMNAKDM4EALOX15MEN1LRAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | FUT6, FUT5, GALNT6 | LMNA 1327/4885MAPK1 2092/4885KDM4E 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.